FDA to evaluate Avastin for deadly form of brain cancer

03/10/2009 | Forbes

An FDA panel is scheduled March 31 to review Genentech's application to promote Avastin as a treatment for a deadly form of brain cancer called glioblastoma multiforme. Avastin, which is approved to treat colon, breast and lung cancers, generated $2.69 billion in U.S. sales last year.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
CT
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Senior Counsel – Regulatory Affairs
RAI Services Company
Winston-Salem, NC